Tiper Irina, Kourout Moussa, Lanning Bryan, Fisher Carolyn, Konduru Krishnamurthy, Purkayastha Anjan, Kaplan Gerardo, Duncan Robert
Division of Emerging and Transfusion-Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States of America.
OpenBox Bio, Vienna, VA, United States of America.
PLoS One. 2022 Feb 10;17(2):e0263732. doi: 10.1371/journal.pone.0263732. eCollection 2022.
Filoviruses are emerging pathogens that cause acute fever with high fatality rate and present a global public health threat. During the 2013-2016 Ebola virus outbreak, genome sequencing allowed the study of virus evolution, mutations affecting pathogenicity and infectivity, and tracing the viral spread. In 2018, early sequence identification of the Ebolavirus as EBOV in the Democratic Republic of the Congo supported the use of an Ebola virus vaccine. However, field-deployable sequencing methods are needed to enable a rapid public health response. Resequencing microarrays (RMA) are a targeted method to obtain genomic sequence on clinical specimens rapidly, and sensitively, overcoming the need for extensive bioinformatic analysis. This study presents the design and initial evaluation of an ebolavirus resequencing microarray (Ebolavirus-RMA) system for sequencing the major genomic regions of four Ebolaviruses that cause disease in humans. The design of the Ebolavirus-RMA system is described and evaluated by sequencing repository samples of three Ebolaviruses and two EBOV variants. The ability of the system to identify genetic drift in a replicating virus was achieved by sequencing the ebolavirus glycoprotein gene in a recombinant virus cultured under pressure from a neutralizing antibody. Comparison of the Ebolavirus-RMA results to the Genbank database sequence file with the accession number given for the source RNA and Ebolavirus-RMA results compared to Next Generation Sequence results of the same RNA samples showed up to 99% agreement.
丝状病毒是新兴病原体,可引发急性发热且致死率高,对全球公共卫生构成威胁。在2013 - 2016年埃博拉病毒疫情期间,基因组测序有助于研究病毒进化、影响致病性和传染性的突变以及追踪病毒传播。2018年,在刚果民主共和国对埃博拉病毒进行早期序列鉴定,确定其为埃博拉病毒,这支持了埃博拉病毒疫苗的使用。然而,需要可在现场部署的测序方法来实现快速的公共卫生应对。重测序微阵列(RMA)是一种靶向方法,可快速、灵敏地获取临床标本的基因组序列,无需进行广泛的生物信息学分析。本研究介绍了一种用于对四种可导致人类疾病的埃博拉病毒的主要基因组区域进行测序的埃博拉病毒重测序微阵列(Ebolavirus - RMA)系统的设计和初步评估。通过对三种埃博拉病毒和两种埃博拉病毒变体的储存库样本进行测序,描述并评估了Ebolavirus - RMA系统的设计。该系统通过对在中和抗体压力下培养的重组病毒中的埃博拉病毒糖蛋白基因进行测序,实现了识别复制病毒中基因漂移的能力。将Ebolavirus - RMA的结果与Genbank数据库中给出的源RNA登录号的序列文件进行比较,以及将Ebolavirus - RMA的结果与相同RNA样本的下一代测序结果进行比较,结果显示一致性高达99%。